ATG3: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: ATG3

NCBI ID: G64422

ATG3

ATG3: A Potential Drug Target for Cancer and Neurodegenerative Diseases

ATG3 (Aurora-Tiposin-GTPase-3) is a protein that is expressed in various tissues throughout the body. It is a key component of the microtubules, which are essential for cell division and transport of organelles within cells. ATG3 has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The microtubules are composed of a protein called tubulin and a protein called microtubule-associated protein 2 (MAP2). MAP2 is a protein that is involved in the regulation of microtubule dynamics and functions, while tubulin provides the structural stability necessary for the microtubules to function. The dynamic regulation of microtubules is critical for various cellular processes, including cell division, intracellular transport, and cell survival.

ATG3 is a protein that is involved in the regulation of microtubule dynamics and stability. It is a key component of the microtubules and plays a role in the stability of microtubules. ATG3 helps to keep the microtubules in a stable state, which is essential for the proper functioning of the cell.

ATG3 has been shown to play a role in a variety of diseases and conditions, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that high levels of ATG3 are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, ATG3 has been shown to be involved in the regulation of cancer cell division, which could make it an attractive target for cancer therapies.

In addition to its role in disease, ATG3 has also been shown to be a potential drug target. Researchers have identified several potential drug candidates that target ATG3, and these drugs have been shown to have therapeutic effects in a variety of conditions, including cancer, neurodegenerative diseases, and developmental disorders. For example, one drug candidate, called BK-822, is currently being investigated for its potential use in the treatment of neurodegenerative diseases, including Alzheimer's disease.

The identification of ATG3 as a potential drug target is an exciting area of research, with implications for the treatment of a variety of diseases. Further studies are needed to fully understand the role of ATG3 in disease and to develop effective therapies that target this protein.

Protein Name: Autophagy Related 3

Functions: E2 conjugating enzyme required for the cytoplasm to vacuole transport (Cvt), autophagy, and mitochondrial homeostasis. Responsible for the E2-like covalent binding of phosphatidylethanolamine to the C-terminal Gly of ATG8-like proteins (GABARAP, GABARAPL1, GABARAPL2 or MAP1LC3A). The ATG12-ATG5 conjugate plays a role of an E3 and promotes the transfer of ATG8-like proteins from ATG3 to phosphatidylethanolamine (PE). This step is required for the membrane association of ATG8-like proteins. The formation of the ATG8-phosphatidylethanolamine conjugates is essential for autophagy and for the cytoplasm to vacuole transport (Cvt). Preferred substrate is MAP1LC3A. Also acts as an autocatalytic E2-like enzyme, catalyzing the conjugation of ATG12 to itself, ATG12 conjugation to ATG3 playing a role in mitochondrial homeostasis but not in autophagy. ATG7 (E1-like enzyme) facilitates this reaction by forming an E1-E2 complex with ATG3. Promotes primary ciliogenesis by removing OFD1 from centriolar satellites via the autophagic pathway

The "ATG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets